Bioloom (Seed)
Funding Details
- Date Award
- September 30, 2023
- Vertical
- Biotech
- Funding URL
- View Funding Page
- Premoney Valuation
- $1,000,000
- Valuation
- $15,000,000
- Funding Amount:
- $2,500,000
Company Info
- Founding Year
- 2019
- Traction
- Bioloom has successfully completed preclinical studies and is preparing for Phase 1 clinical trials. The company has garnered significant interest from key opinion leaders in the autoimmune disease space and has established collaborations with leading academic institutions.
- Organizations Involved
- SOSV, Y Combinator, Stanford University
- Founders
- Alice Chen, David Lee
- Company Description
- Bioloom is a biotech company specializing in developing novel therapeutics for autoimmune diseases by leveraging its proprietary platform that combines machine learning algorithms with high-throughput screening technologies. The company's approach enables the rapid identification of potential drug candidates with high efficacy and low toxicity, offering a promising solution for patients suffering from autoimmune disorders.
- Market
- Healthcare
- Location
- San Francisco, CA, US
- Coinvestors
- SOSV, Y Combinator